NCT03003676 · Interventional trial
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Overall registry status Completed
Phase 1
Conditions Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Delaware Valley sites
- Fox Chase Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory